Efeito combinado do ácido zoledrônico e do alfacalcidol no tratamento da osteoporose por desuso em ratos

Khajuria, Deepak Kumar; Disha, Choudhary; Razdan, Rema; Mahapatra, D. Roy

doi:10.1016/j.rbr.2014.08.007

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have reported that bisphosphonates prevent bone loss during bed rest and space flights [13,14]. Combination treatment comprising an anti-bone resorptive drug and active vitamin D analogue has been shown to prevent bone loss in the hind limbs of immobilized rats [15]. In our study, 93% of patients were receiving an anti-resorptive drug including denosmab, a bisphosphonate, and selective estrogen modulator.…”

Section: Discussionmentioning

confidence: 69%

Short-Term Impact of Staying Home on Bone Health in Patients With Osteoporosis During a State of Emergency Declaration Due to COVID-19 in Kanagawa, Japan

Yokozeki¹,

Uchida²,

Miyagi³

et al. 2020

Cureus

View full text Add to dashboard Cite

Background On April 16, 2020, the Japanese government declared a state of emergency due to the spread of COVID-19 infection, leading prefectural governors to announce a stay-at-home order for 39 days until May 25, 2020. As physical inactivity is a risk factor for osteoporosis, we investigated the short-term impact of the stay-at-home order on bone health among patients with osteoporosis in our hospital in Kanagawa prefecture.

show abstract

Section: Discussionmentioning

confidence: 69%

Short-Term Impact of Staying Home on Bone Health in Patients With Osteoporosis During a State of Emergency Declaration Due to COVID-19 in Kanagawa, Japan

Yokozeki¹,

Uchida²,

Miyagi³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Выявлено, что совместное назначение золедроновой кислоты и альфакальцидола крысам при экспериментальном остеопорозе сопровождается более выраженным положительным воздействием на микроархитектонику губчатой и кортикальной костной ткани, чем монотерапия. Требуются клинические работы, посвященные изучению эффективности комбинированной терапии остеопороза золедроновой кислотой и активными метаболитами витамина D [59,60].…”

Section: золедроновая кислота в составе комбинированной терапииunclassified

Zoledronic acid for osteoporosis and associated low-energy fractures

et al. 2022

View full text Add to dashboard Cite

Zoledronic acid is a third-generation amino-containing BF that has been used to treat patients with osteoporosis for more than 15 years. Over the years, numerous experimental and clinical studies have proven the high efficacy of the drug in osteoporosis, both in women of various age groups, and in men, with primary and secondary osteoporosis, in patients with varying degrees of bone loss and risk of fractures. Intravenous infusions of zoledronic acid have been shown to result in a rapid gain of bone mass, a significant reduction in the risk of low-energy fractures of the vertebrae (spine), proximal femoral and nonvertebral fractures on the whole. However, in recent years, the use of the drug has significantly decreased, which is associated both with the lack of awareness of primary care physicians about the possibilities of this drug, and the fear of such complications of its use as atypical fractures and osteonecrosis of the jaw bones. The presented review aims to increase the knowledge of physicians regarding the mechanism of action of zoledronic acid, the regimens for prescribing the drug in various forms of osteoporosis and fractures against its background. The given clinical example shows the ability of zoledronic acid (osteostatics) to increase the mass of not only cancellous, but also the cortical bone of the proximal femur, which increases the role of zoledronic acid in the prevention of recurrent fractures. On top of that, the prolonged effect of the drug allows, when the desired therapeutic effect is achieved, to reduce the frequency of prescribing according to the ‘drug holiday’ principal, decreasing economic expenditures and medical and social burden.

show abstract

Review of the Mechanism of Action and Use of Bisphosphonates in Horses

Yocom

Contino

Kawcak

2023

Journal of Equine Veterinary Science

View full text Add to dashboard Cite

Efeito combinado do ácido zoledrônico e do alfacalcidol no tratamento da osteoporose por desuso em ratos

Abstract: These data suggest that combination therapy with ZOL plus ALF represents a potentially useful therapeutic option for the treatment of disuse osteoporosis.

Cited by 6 publications

References 20 publications

Short-Term Impact of Staying Home on Bone Health in Patients With Osteoporosis During a State of Emergency Declaration Due to COVID-19 in Kanagawa, Japan

Short-Term Impact of Staying Home on Bone Health in Patients With Osteoporosis During a State of Emergency Declaration Due to COVID-19 in Kanagawa, Japan

Zoledronic acid for osteoporosis and associated low-energy fractures

Review of the Mechanism of Action and Use of Bisphosphonates in Horses

Contact Info

Product

Resources

About